News

Each therapy will feature a mixture of synthetic messenger RNAs (mRNAs). BioNTech will receive $60m in upfront and near-term milestone payments. The company could also receive more than

The formulation for the spray includes three important ingredients which get absorbed quicker, penetrate deep to reach the source of pain and reduce inflammation. Nise D Spray will

Dyax develops plasma kallikrein (pKal) inhibitors for the treatment of hereditary angioedema (HAE), a rare and potentially life-threatening disease that causes swelling. The deal gives Shire access to

Cardioxyl is focused on the discovery and development of novel therapeutic agents to treat cardiovascular disease. The transaction, which is expected to close in the fourth quarter, gives

The recall is specific to the Allerject epinephrine auto-injector, manufactured by Sanofi and does not apply to EpiPen. Pfizer Canada has already shipped its current EpiPen inventory to

Alexza and Teva also plan to restructure the obligations under the outstanding note from Teva. Alexza and Teva are working on a transition agreement to continue product availability

In October 2013, Warner Chilcott plc, Warner Chilcott Sales’ indirect parent corporation, became a wholly-owned subsidiary of Actavis plc. In March 2015, Actavis plc completed an acquisition of

Chaudhuri will report to Rajiv Malik, president of Mylan. Chaudhuri joins Mylan from GlaxoSmithKline (GSK) Consumer Healthcare, where he served for nearly three decades, and brings to Mylan

The other investors in PrEP Biopharm include Johnson & Johnson Innovation – JJDC and US-based angel investors. hVIVO will acquire a significant interest in PrEP Biopharm for £14m,